Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 120

1.

The sirtuin inhibitor tenovin-6 upregulates death receptor 5 and enhances cytotoxic effects of 5-fluorouracil and oxaliplatin in colon cancer cells.

Ueno T, Endo S, Saito R, Hirose M, Hirai S, Suzuki H, Yamato K, Hyodo I.

Oncol Res. 2014;21(3):155-64. doi: 10.3727/096504013X13854886566598.

PMID:
24512730
[PubMed - indexed for MEDLINE]
2.

Treatment of human colon cancer xenografts with TRA-8 anti-death receptor 5 antibody alone or in combination with CPT-11.

Oliver PG, LoBuglio AF, Zinn KR, Kim H, Nan L, Zhou T, Wang W, Buchsbaum DJ.

Clin Cancer Res. 2008 Apr 1;14(7):2180-9. doi: 10.1158/1078-0432.CCR-07-1392.

PMID:
18381960
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.

Na YS, Jung KA, Kim SM, Hong YS, Ryu MH, Jang SJ, Moon DH, Cho DH, Kim JC, Lee JS, Kim TW.

Cancer Chemother Pharmacol. 2011 Aug;68(2):389-98. doi: 10.1007/s00280-010-1495-6. Epub 2010 Nov 3.

PMID:
21046105
[PubMed - indexed for MEDLINE]
4.

Effects of the HDAC inhibitor CG2 in combination with irinotecan, 5-fluorouracil, or oxaliplatin on HCT116 colon cancer cells and xenografts.

Na YS, Kim SM, Jung KA, Yang SJ, Hong YS, Ryu MH, Ro S, Cho DH, Kim JC, Jin DH, Lee JS, Kim TW.

Oncol Rep. 2010 Dec;24(6):1509-14.

PMID:
21042746
[PubMed - indexed for MEDLINE]
5.

Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice.

Naka T, Sugamura K, Hylander BL, Widmer MB, Rustum YM, Repasky EA.

Cancer Res. 2002 Oct 15;62(20):5800-6.

PMID:
12384541
[PubMed - indexed for MEDLINE]
Free Article
6.

Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL.

Ravi R, Jain AJ, Schulick RD, Pham V, Prouser TS, Allen H, Mayer EG, Yu H, Pardoll DM, Ashkenazi A, Bedi A.

Cancer Res. 2004 Dec 15;64(24):9105-14.

PMID:
15604280
[PubMed - indexed for MEDLINE]
Free Article
7.

Pemetrexed disodium combined with oxaliplatin, SN38, or 5-fluorouracil, based on the quantitation of drug interactions in human HT29 colon cancer cells.

Raymond E, Louvet C, Tournigand C, Coudray AM, Faivre S, De Gramont A, Gespach C.

Int J Oncol. 2002 Aug;21(2):361-7.

PMID:
12118332
[PubMed - indexed for MEDLINE]
8.

2-methoxy-5-amino-N-hydroxybenzamide sensitizes colon cancer cells to TRAIL-induced apoptosis by regulating death receptor 5 and survivin expression.

Stolfi C, Caruso R, Franzè E, Rizzo A, Rotondi A, Monteleone I, Fantini MC, Pallone F, Monteleone G.

Mol Cancer Ther. 2011 Oct;10(10):1969-81. doi: 10.1158/1535-7163.MCT-11-0316. Epub 2011 Aug 4.

PMID:
21817114
[PubMed - indexed for MEDLINE]
Free Article
9.

Antitumor effects of a sirtuin inhibitor, tenovin-6, against gastric cancer cells via death receptor 5 up-regulation.

Hirai S, Endo S, Saito R, Hirose M, Ueno T, Suzuki H, Yamato K, Abei M, Hyodo I.

PLoS One. 2014 Jul 17;9(7):e102831. doi: 10.1371/journal.pone.0102831. eCollection 2014.

PMID:
25033286
[PubMed - in process]
Free PMC Article
10.

MSH3 mismatch repair protein regulates sensitivity to cytotoxic drugs and a histone deacetylase inhibitor in human colon carcinoma cells.

Park JM, Huang S, Tougeron D, Sinicrope FA.

PLoS One. 2013 May 28;8(5):e65369. doi: 10.1371/journal.pone.0065369. Print 2013.

PMID:
23724141
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Delivery of sTRAIL variants by MSCs in combination with cytotoxic drug treatment leads to p53-independent enhanced antitumor effects.

Yu R, Deedigan L, Albarenque SM, Mohr A, Zwacka RM.

Cell Death Dis. 2013 Feb 21;4:e503. doi: 10.1038/cddis.2013.19.

PMID:
23429289
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

P53-mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells.

Toscano F, Fajoui ZE, Gay F, Lalaoui N, Parmentier B, Chayvialle JA, Scoazec JY, Micheau O, Abello J, Saurin JC.

Oncogene. 2008 Jul 10;27(30):4161-71. doi: 10.1038/onc.2008.52. Epub 2008 Mar 17.

PMID:
18345033
[PubMed - indexed for MEDLINE]
13.

Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress.

Kopetz S, Lesslie DP, Dallas NA, Park SI, Johnson M, Parikh NU, Kim MP, Abbruzzese JL, Ellis LM, Chandra J, Gallick GE.

Cancer Res. 2009 May 1;69(9):3842-9. doi: 10.1158/0008-5472.CAN-08-2246. Epub 2009 Apr 21.

PMID:
19383922
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin.

Zeghari-Squalli N, Raymond E, Cvitkovic E, Goldwasser F.

Clin Cancer Res. 1999 May;5(5):1189-96.

PMID:
10353756
[PubMed - indexed for MEDLINE]
Free Article
15.

Dovitinib synergizes with oxaliplatin in suppressing cell proliferation and inducing apoptosis in colorectal cancer cells regardless of RAS-RAF mutation status.

Gaur S, Chen L, Ann V, Lin WC, Wang Y, Chang VH, Hsu NY, Shia HS, Yen Y.

Mol Cancer. 2014 Feb 4;13:21. doi: 10.1186/1476-4598-13-21.

PMID:
24495750
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

The synergistic effects of low-dose irinotecan and TRAIL on TRAIL-resistant HT-29 colon carcinoma in vitro and in vivo.

Zhu H, Zhao F, Yu S, He J, Deng L, Yi C, Huang Y.

Int J Mol Med. 2012 Nov;30(5):1087-94. doi: 10.3892/ijmm.2012.1105. Epub 2012 Aug 21.

PMID:
22922573
[PubMed - indexed for MEDLINE]
17.

Comparison between triple therapy with octreotide, galanin and serotonin vs. irinotecan or oxaliplatin in combination with 5-fluorouracil/leukovorin in human colon cancer.

El-Salhy M, Hilding L, Royson H, Tjomsland V.

Int J Oncol. 2005 Sep;27(3):687-91.

PMID:
16077917
[PubMed - indexed for MEDLINE]
18.

Identification of a potent epigenetic biomarker for resistance to camptothecin and poor outcome to irinotecan-based chemotherapy in colon cancer.

Miyaki Y, Suzuki K, Koizumi K, Kato T, Saito M, Kamiyama H, Maeda T, Shibata K, Shiya N, Konishi F.

Int J Oncol. 2012 Jan;40(1):217-26. doi: 10.3892/ijo.2011.1189. Epub 2011 Sep 7.

PMID:
21901246
[PubMed - indexed for MEDLINE]
19.

Different effects of epigenetic modifiers on the cytotoxicity induced by 5-fluorouracil, irinotecan or oxaliplatin in colon cancer cells.

Ikehata M, Ogawa M, Yamada Y, Tanaka S, Ueda K, Iwakawa S.

Biol Pharm Bull. 2014;37(1):67-73. Epub 2013 Oct 29.

PMID:
24172061
[PubMed - indexed for MEDLINE]
Free Article
20.

Tenovin-D3, a novel small-molecule inhibitor of sirtuin SirT2, increases p21 (CDKN1A) expression in a p53-independent manner.

McCarthy AR, Sachweh MC, Higgins M, Campbell J, Drummond CJ, van Leeuwen IM, Pirrie L, Ladds MJ, Westwood NJ, Laín S.

Mol Cancer Ther. 2013 Apr;12(4):352-60. doi: 10.1158/1535-7163.MCT-12-0900. Epub 2013 Jan 15.

PMID:
23322738
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk